BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

CARsgen Reports Promising Early Data for Allogeneic BCMA CAR-T CT0596 in Relapsed/Refractory Multiple Myeloma

CARsgen Therapeutics Holdings Limited a company focused on developing innovative CAR T-cell therapies, announces preliminary clinical data for CT0596...

May 12, 2025 | News

Connext Completes Phase 1 for CNT201, Eyes Phase 2 Launch and Expansion into Peyronie’s Disease

Conducted under U.S. FDA-cleared IND– Plans for Phase 2 initiation in Q3 2025 and expansion into Peyronie's disease Connext, a clinical s...

May 09, 2025 | News

TiumBio’s Merigolix Shows Phase 2 Success in Asia for Uterine Fibroids

TiumBio (KRX: 321550.KQ), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for patients with rare a...

May 08, 2025 | News

AstraZeneca and Daiichi Sankyo’s ENHERTU Demonstrates Superior pCR in Early HER2+ Breast Cancer in Phase 3 DESTINY-Breast11 Trial

Positive topline results from the DESTINY-Breast11 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) followed by paclitaxel, trastu...

May 08, 2025 | News

Andelyn Biosciences Supports Nationwide Children's Novel AML Therapy with AAV Manufacturing

Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has manufac...

May 08, 2025 | News

SK Bioscience to Lead Korea’s Avian Influenza Vaccine Development Under KRW 5.25B Pandemic Preparedness Program

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that it has bee...

May 07, 2025 | News

Taiwan’s Formosa Pharmaceuticals Partners with Apotex to Commercialize APP13007 in Mexico for Post-Ocular Surgery Treatment

Taiwan-based Formosa Pharmaceuticals announced that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), ...

May 07, 2025 | News

AGC Biologics Partners with South Korea’s Novelty Nobility to Advance Bispecific Antibody Program Across Europe and Asia

Global CDMO supports South Korean company on a multiphase project at its Copenhagen and Chiba sites AGC Biologics, your friendly CDMO expert, an...

May 06, 2025 | News

Beijing Tide Begins Phase II Trial of First-in-Class Non-Opioid CPSP Drug TRD205

Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class ...

May 06, 2025 | News

Nutshell Therapeutics Receives FDA IND Clearance for First-in-Human Trial of NTS071 Targeting p53 Y220C Mutation

Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical ...

May 05, 2025 | News

InnoCare’s Zurletrectinib Granted Priority Review in China for NTRK Fusion-Positive Solid Tumors

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced that its new genera...

May 05, 2025 | News

AstraZeneca’s BREZTRI AEROSPHERE Demonstrates Significant Lung Function Gains in Phase III Asthma Trials

Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose tripl...

May 05, 2025 | News

Genocury Biotech’s In Vivo CD19 CAR-T Achieves Complete Remission in R/R DLBCL Without Lymphodepletion

Genocury Biotech today revealed groundbreaking clinical data from its noval in vivo CD19 CAR-T therapy in relapsed/refractory diffuse large ...

May 01, 2025 | News

Keymed Biosciences Advances CDH17-Targeted ADC CM518D1 Into Phase I/II Trials for Solid Tumors in China

Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) develop...

April 28, 2025 | News

Stay Connected